Skip to main content
SpringerLink
Log in

Pharmacodynamic Evaluation: Drug Dependency and Addiction

  • Reference work entry
  • First Online:
Drug Discovery and Evaluation: Methods in Clinical Pharmacology

  • 969 Accesses

Abstract

The intake of psychoactive substances has accompanied mankind since the dawn of human race. Different psychoactive substances have been extracted and synthesized in human history, and their pharmacodynamic properties have been studied thoroughly. This chapter presents the current knowledge on the pharmacodynamic profile of the most common illicit and recreational drugs and their influence on drug dependency and addiction. The substances with abuse potential grow exponentially. Our clinical and practical knowledge has still a long way to go in catching up with these realities. The dynamic interactions between different drugs observed in vitro cannot be fully replicated in vivo. We rely on randomized clinical trials, case reports, and own clinical experience with patients. Different clinical scenarios could provide further evidence and hypotheses regarding the sought and adverse effects of substances, their interactions with legal drugs and medications, and their impact on different stages of metabolism. In this chapter we attempted to summarize the available reliable data and suggest some ideas for future observation and research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References and Further Reading

  • Anis NA, Berry NSC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 79:565–575

    Google Scholar 

  • Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group (2007) Carcinogenicity of alcoholic beverages. Lancet Oncol 8:292–293

    Google Scholar 

  • Baumann MH, Soris E, Watterson LR et al (2014) Bath salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34(46):15150–15158

    Google Scholar 

  • Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4(4):156–169

    Google Scholar 

  • Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease and therapeutics. Annu Rev Pharmacol Toxicol 49:57–71

    Google Scholar 

  • Blessing WW, Seaman B, Pedersen NP, Ootsuka Y (2003) Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4 - methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci 23(15):6385–91

    Google Scholar 

  • Brox B, Ellenbroek B (2018) A genetic reduction in the serotonin transporter differentially influences MDMA and heroin induced behaviours. Psychopharmacology (Berl) 235(7):1907–1914

    Google Scholar 

  • Calipari ES, Ferris MJ (2013) Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci 33(21):8923–8925

    Google Scholar 

  • Campbell JE, Cohall D (2017) Pharmacodynamics – a pharmacognosy perspective, Chapter 26. In: Pharmacognosy. Fundamentals, applications, strategies. Academic, Boston, pp 513–525

    Google Scholar 

  • Capasso R, Borrelli F, Capasso F et al (2006) The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the Guinea-pig ileum. Neurogastroenterol Motil 18(1):69–75

    Google Scholar 

  • Casey ER, Scott MG, Tang S, Mullins ME (2011) Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol 7(2):105–108

    Google Scholar 

  • Ciudad-Roberts A, Camarasa J, Ciudad CJ et al (2015) Alcohol enhances the psychostimulant and conditioning effects of mephedrone in adolescent mice; postulation of unique roles of D receptors and BDNF in place preference acquisition. Br J Pharmacol 172:4970–4984

    Google Scholar 

  • de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26(2):137–144

    Google Scholar 

  • Dean A (2006) Illicit drugs and drug interactions. Pharmacist 25(9):684–689. www.erowid.org/psychoactives

  • DeVane CL (2016) Clinical pharmacokinetics and pharmacodynamics of anxiolytics and sedative/hypnotics. In: Jann M, Penzak S, Cohen L (eds) Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents. Adis, Cham, pp 247–266

    Chapter  Google Scholar 

  • Dumas EO, Pollack GM (2008) Opioid tolerance: a pharmacokinetic/pharmacodynamic perspective. AAPS J 10(4):537–551

    Google Scholar 

  • Edenberg HJ (2007) The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 30(1):5–13

    Google Scholar 

  • Feng XQ, Zhu LL, Zhou Q (2017) Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res 10:1225–1239. https://doi.org/10.2147/JPR.S138698eCollection2017.

  • Ganetsky M et al (2013) Effect of excipients of acetaminophen metabolism and its’ implications for prevention of liver injury. J Clini Pharmacol 53(4):413–20

    Google Scholar 

  • Galleli L, Gratteti S, Siniscalchi A, Cione E, Sirico S, Seminara P, Caroleo MC, De Sarro G (2017) Curr Drug Abuse Rev 10(1):25–30

    Google Scholar 

  • Gay GR, Inaba DS, Sheppard CW, Newmeyer JA (1975) Cocaine: history, epidemiology, human pharmacology, and treatment. A perspective on a new debut for an old girl. Clin Toxicol 8(2):149–178

    Google Scholar 

  • Ghelardini C, Mannelli LDC, Bianchi E (2015) The pharmacological basis of opioids. Clin Cases Miner Bone Metab 12(3):219–221

    Google Scholar 

  • Gosnell BA, Kotz CM, Billington CJ, Levine AS (2013) Handbook of biologically active peptides, 2nd Ed. In: Abbaj Kastin (Ed), Ingestive Peptides. Academic Press, Elsevier, pp 1149–1154

    Google Scholar 

  • Griffin AE III, Kaye AM, Bueno FR, Kaye AD (2013) Benzodiazepine pharmacology and central nervous system – mediated effects. Ochsner J 13(2):214–223

    Google Scholar 

  • Gurusamy U, Shewade DG (2014) Chapter 46: Pharmacogenomics in India, Handbook of Oharmacogenomics nad Stratified Medicine, Elsevier

    Google Scholar 

  • Harrison AA, Liem YT, Markou A (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25(1):55–71

    Google Scholar 

  • Härtel-Petri R, Krampe-Scheidler A, Braunwarth WD, Havemann-Reinecke U, Jeschke P, Looser W, Mühlig S, Schäfer I, Scherbaum N, Bothe L, Schaefer C, Hamdorf W (2017a) Evidence-based guidelines for the pharmacologic management of methamphetamine dependence, relapse prevention, chronic methamphetamine-related, and comorbid psychiatric disorders in post-acute settings. Pharmacopsychiatry 50(3):96–104

    Google Scholar 

  • Härtel-Petri R, Krampe-Scheidler A, Braunwarth WD, Havemann-Reinecke U, Jeschke P, Looser W, Mühlig S, Schäfer I, Scherbaum N, Bothe L, Schaefer C, Hamdorf W (2017b) Evidence-based guidelines for the pharmacologic management of methamphetamine dependence, relapse prevention, chronic methamphetamine-related, and comorbid psychiatric disorders in post-acute settings. Pharmacopsychiatry 50:96–104

    Google Scholar 

  • Higuchi S, Matsushita S, Murayama M et al (1995) Alcohol and aldehyde dehydrogenase polymorphisms and the risk of alcoholism. Am J Psychiatry 152:1219–1221

    Google Scholar 

  • Haufroid V et al (2002) Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene. Pharmacogenetics 12(9):691–702

    Google Scholar 

  • Jevtovic-Todorovic V, Todorovic SM, Mennerick S et al (1998) Nitrous oxide (laughing gas) is a NMDA antagonist, neuroprotector and neurotoxin. Nat Med 4(4):460–463

    Google Scholar 

  • Kavannagh D, Goodship THJ, Richards A (2006) Atypical haemolytic uraemic syndrome. Br Med Bull 77–78:5–22

    Google Scholar 

  • Kim HR, Son BH, Lee SY et al (2012) The role of p53 in marijuana smoke condensates-induced genotoxicity and apoptosis. Environ Health Toxicol 27:c2012017

    Google Scholar 

  • Kishi T, Matsuda Y, Iwata N, Correll CU (2013) Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 74(12):e1169–e1180

    Google Scholar 

  • Koob GF, Le Moal M (2006) Neurobiology of Addiction. Academic Press, Imprint of Elsevier 92:101–4495

    Google Scholar 

  • Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD (1990) Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 112(12):897–903

    Google Scholar 

  • Li JH, Lin LF (1998) Genetic toxicology of abused drugs: a brief review. Mutagenesis 13(6):557–565

    Google Scholar 

  • Lindsey WT, Stewart D, Childress D (2012) Drug interactions between common illicit drugs and prescription therapies. Am J Drug Alcohol Abuse 38(4):334–343

    Google Scholar 

  • McGraw J (2014) Chapter 16: CYP450 and Ethnicity, Handbook of Pharmacogenomics and Stratified Medicine, Elsevier

    Google Scholar 

  • McCance-Katz EF, Jatlow P, Rainey P, Friedland G (1998) Methadone effects on zidovudine (AZT) disposition (ACTG 262). J Acquir Immune Defic Syn Hum Retrovirol 18:435–443

    Google Scholar 

  • McGuire P et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175(3):225–231

    Google Scholar 

  • Medicines and Healthcare products Regulatory Agency (2016) Citalopram: suspected drug interaction with cocaine. Drug Saf Update 9(12):2

    Google Scholar 

  • Mittal B, et al, Advances in Clinical Chemistry; Chapter Four: Cytochrome P450 in Cancer Susceptibility and Treatment. Volume 71 Ed by Makowski GS, (2015), Elsevier.

    Google Scholar 

  • Mollereau C, Roumy M, Zajac JM (2005) Opioid-modulating peptides: mechanisms of action. Curr Top Chem 5(3):341–355

    Google Scholar 

  • Moon KH, Upreti VV, Yu LR et al (2008) Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-mediated mitochondrial dysfunction in rat liver. Proteomics 8(18):3906–3918

    Google Scholar 

  • Nestler EJ (2005) The neurobiology of cocaine addiction. Sci Pract Perspect 3(1):4–10

    Google Scholar 

  • Pani PP, Trogu E, Vecchi S, Amato L (2011) Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev (12):CD002950

    Google Scholar 

  • Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65(4):1257–1317

    Google Scholar 

  • Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1–51

    Google Scholar 

  • Pomara C, Cassano T, D’Errico S et al (2012) Data available on the extent of cocaine use and dependence: biochemistry, pharmacologic effects and global burden of disease of cocaine abusers. Cur Med Chem 19(33):5647–5657

    Google Scholar 

  • Powledge TM (1999) Addiction and the brain. Bioscience 49(7):513–519

    Google Scholar 

  • Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8(1):33–42

    Google Scholar 

  • Quinn DI, Wodak A, Day RO (1997) Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 33(5):344–400

    Google Scholar 

  • Ratina A, Mandrekar P (2017) Alcohol and cancer: mechanisms and therapies. Biomolecules 7:(3)

    Google Scholar 

  • Reece AS (2009) Chronic toxicology of cannabis. Clin Toxicol 47:517–524

    Google Scholar 

  • Reece AS, Hulse GK (2016) Chromothripsis and epigenomics complete causality criteria for cannabis and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res 789:1–11

    Google Scholar 

  • Richards JR, Garber D, Laurin EG, Albertson TE, Derlet RW, Amsterdam EA, Olson KR, Ramoska EA, Lange RA (2016) Treatment of cocaine cardiovascular toxicity: a systematic review. Clin Toxicol (Phila) 54(5):345–364

    Google Scholar 

  • Rietjens SJ, Hondebrink L, Westerink RHS, Meulenbelt J (2012) Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions. Crit Rev Toxicol 42 (10):854–76

    Google Scholar 

  • Robison AJ, Nestler EJ (2011) Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 12(11):623–637

    Google Scholar 

  • Rudnik G, Wall SC (1992) The molecular mechanism of “ecstasy” [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci 89:1817–1821

    Google Scholar 

  • Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG (2008) Pharmacokinetics in drug discovery. J Pharm Sci 97(2):654–690

    Google Scholar 

  • Schmidt CJ, Taylor VL (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36:4095–4102

    Google Scholar 

  • Schwab M (2011) Encyclopedia of cancer, 3rd edn. Springer, Berlin

    Book  Google Scholar 

  • Sharma P, Murthy P, Bharath S (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 7(4):149–156

    Google Scholar 

  • Sleigh J, Harley M, Voss L, Denny B (2014) Ketamine – more mechanisms of action than just NMDA blockade. Trends Anest Crit Care 4(2–3):76–81

    Google Scholar 

  • Status and Trend Analysis of Illicit Drug Markets (2015) World drug report. http://www.unodc.org/documents/wdr2015/WDR15_Drug_use_health_consequences.pdf

  • Stein C, Schäfer M, Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9(8):1003–1008, Publisher Iztok-Zapad, 5 Stara Planina Str, 2nd Floor, Sofia, 1000, Bulgaria, EU; ISBN 978-954-9854-19-0, 248 pp

    Google Scholar 

  • Tenev V (2008) Reference Book on Drug Interactions in Psychiatry and General medical practice. Bulgarian Psychiatric Association, Publisher Iztok-Zapad, 5 Stara Planina Str, 2nd Floor, Sofia, 1000, Bulgaria, EU; ISBN 978-954-9854-19-0, 248 pages

    Google Scholar 

  • Volkow ND, Morales M (2015) The brain on drugs: from reward to addiction. Cell 162:712–725

    Google Scholar 

  • Vonlaufen A, Wilson JS, Pirola RC, Apte MV (2007) Role of alcohol metabolism in chronic pancreatitis. Alcohol Res Health 30(1):48–54

    Google Scholar 

  • Yubero-Lahoz S, Pardo R, Farré M, O’Mahony B, Torrens M, Mustata C et al (2011) Sex differences in 3, 4-methylenedioxymethamphetamine(MDMA; ecstasy)-induced MDMA, methamphetamine, and CYP2D6 cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 50:319–329

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University Hospital, University of Iowa, Iowa city, IA, USA

    V. Tenev

  2. University Hospital Alexandrovska, Clinic of Nephrology, Medical University, Sofia, Bulgaria

    M. Nikolova

Authors
  1. V. Tenev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Nikolova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Tenev .

Editor information

Editors and Affiliations

  1. CorDynamics, Dieburg, Germany

    Franz J. Hock

  2. CorDynamics, Chicago, IL, USA

    Michael R. Gralinski

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Tenev, V., Nikolova, M. (2020). Pharmacodynamic Evaluation: Drug Dependency and Addiction. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-68864-0_49

Download citation

Publish with us

Policies and ethics

Search

Navigation